Content: 

Today, Syncell Biotech celebrated the grand opening of its headquarters at the Taipei Biotechnology Park, following the inauguration of its office in the Greater Boston area last month. This milestone further solidifies Syncell's foundation for global market expansion. Founder and CEO Jung-Chi Liao, alongside industry leaders, partners, and media representatives, shared recent achievements and future prospects. The event featured remarks by Dr. Pen-Chyr Yang, an academician at Academia Sinica and Vice President of the Biomedical Technology and Device Research Association, who expressed high expectations for Syncell's impact on the biomedical field.   

CEO Jung-Chi Liao emphasized Syncell's commitment to attracting top talent domestically and internationally, leveraging Taiwan's strengths in instrument development and manufacturing, coupled with elite global sales teams. With their innovative proteomics technology, Syncell aims to become a leading player in the international protein biotechnology instrumentation market. Key investors, including Diamond BioFund, Hermes, Taya, and Darwin-Venture, participated in the ribbon-cutting ceremony.   

In just four years since its inception, Syncell has rapidly completed product development and manufacturing, successfully installing its machines at client sites in the United States. Their technology has matured significantly, being effectively utilized to identify previously unknown protein components related to triple-negative breast cancer, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and fatty liver disease. Due to its outstanding technology, international academic institutions and conferences frequently invite CEO Liao to speak. U.S. investment banks have also begun to take notice, inviting him to participate in high-level biotech instrumentation meetings.   

Recently, Syncell appointed Philippe Lyko, a former senior executive at Illumina and GE, as CFO. Nobel Laureate William Moerner serves as a scientific advisor, while biotech serial entrepreneur Martin Madaus (whose company Millipore was acquired by Merck for $7.2 billion) and successful biotech instrumentation executive Don Kania (whose company FEI was acquired by Thermo Fisher for $4.2 billion) have joined as corporate advisors. The strong team positions Syncell for continued success and innovation in the biotech industry.  

Resource (mandarin): 

新析生技世界頂尖蛋白質定點純化技術成國際主流